scholarly journals Increased tumor cell proliferation in mantle cell lymphoma is associated with elevated insulin-like growth factor 2 mRNA-binding protein 3 expression

2012 ◽  
Vol 25 (9) ◽  
pp. 1227-1235 ◽  
Author(s):  
Elena M Hartmann ◽  
Sílvia Beà ◽  
Alba Navarro ◽  
Vanessa Trapp ◽  
Elías Campo ◽  
...  
Keyword(s):  
Cell Proliferation ◽  
Growth Factor ◽  
Tumor Cell ◽  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Insulin Like Growth Factor ◽  
Tumor Cell Proliferation ◽  
Mrna Binding Protein ◽  
Mantle Cell ◽  
Mrna Binding

Tumor Cell Proliferation (Ki-67 Index) Overcomes Cytology and Growth Pattern As Prognostic Factor in Mantle-Cell Lymphoma – Results from Randomized Trials of the European MCL Network

Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 2977-2977 ◽  
Author(s):  
Eva Hoster ◽  
Andreas Rosenwald ◽  
Francoise Berger ◽  
Heinz-Wolfram Bernd ◽  
Sylvia Hartmann ◽  
...  
Keyword(s):  
Cell Proliferation ◽  
Tumor Cell ◽  
Mantle Cell Lymphoma ◽  
Growth Pattern ◽  
Randomized Trials ◽  
Cell Lymphoma ◽  
Tumor Cell Proliferation ◽  
Ki 67 ◽  
Mantle Cell ◽  
Diffuse Growth

Abstract On Behalf of the European MCL Pathology Panel Introduction: Mantle-cell lymphoma (MCL) is an aggressive B-cell lymphoma with a median overall survival (OS) of 5 years, but clinical course varies considerably. This variability has been partly explained by clinical characteristics forming the MIPI (Hoster et al., JCO 2014), but also biological and histological features such as tumor cell proliferation (Ki-67 index), cytology, or growth pattern (Tiemann et al., BJH 2005). Immuno-chemotherapy induction represents the current standard of care, in younger patients including high-dose cytarabine and followed by autologous stem cell transplantation, whereas older patients benefit from rituximab maintenance (Dreyling et al., Ann Oncol 2013). In 2004, the European MCL Network started two large randomized trials, MCL Younger and MCL Elderly, for previously untreated MCL patients. Histopathological features of diagnostic samples were centrally assessed by the European MCL Pathology Panel. Since MCL is relatively rare, evaluations of prognostic factors were mostly based on smaller, retrospectively collected patient cohorts. We now aimed to comparatively evaluate the prognostic value of Ki-67 index, cytology, and growth pattern using the data of these trials. Methods: The Ki-67 index was counted according to published guidelines (Klapper et al., J Hematopathol 2009). MCL cytology was classified as classic, small-cell (B-CLL-like), pleomorphic (DLBCL-like), or blastic (LB-like) (Vogt and Klapper, Histopathology 2013). MCLs with pleomorphic or blastic cytology were combined to blastoid MCL. The growth pattern was classified as diffuse (≤50% nodular) or non-diffuse (>50% nodular or predominantly mantle-zone pattern). The prognostic relevance of these markers was evaluated with respect to OS, adjusting for MIPI score. Results: Of 1012 trial patients with MCL, Ki-67 index, cytology, or growth pattern were available in 50%, 61%, and 47%, respectively. Reasons for missing information were mainly insufficient material or staining. Median Ki-67 index was 20% (2%-97%). 88% had classic MCL, 2% small-cell, 7% pleomorphic and 3% blastic cytology, summing up to 10% with blastoid MCL. 63% of patients had a diffuse growth pattern. Higher Ki-67 index, blastoid MCL, and diffuse growth were each associated with higher MIPI score. Growth pattern was not clearly associated with Ki-67 index or cytology, whereas pleomorphic (median Ki-67 index 39%, range 7%-90%) or blastic MCL (median 80%, 29%-97%) displayed a substantially higher Ki-67 index compared non-blastoid MCL (median 19%, 2%-95%). In univariable analyses, the adjusted OS hazard ratios for higher Ki-67 index (10% increase), blastoid MCL, or diffuse growth were 1.16 (95% CI 1.09-1.24, p<0.0001), 1.91 (1.34-2.72, p=0.0004), and 1.16 (0.84-1.60, p=0.38), respectively. In multivariable analyses, Ki-67 index was more relevant (adjusted hazard ratio 1.12, 1.04-1.22, p=0.0032) than blastoid MCL (1.46, 0.94-2.29, p=0.095), whereas growth pattern was not prognostic. Accordingly, patients with Ki-67 index ≥30% had substantially inferior OS than patients with Ki-67 index <30% in both, blastoid and non-blastoid MCL (Figure 1). Conclusions: In a large cohort of MCL patients treated in randomized trials according to current guidelines, tumor cell proliferation (Ki-67 index) was a powerful prognostic marker, superior to cytology and growth pattern, and independent of clinical prognostic factors. The Ki-67 index further stratified patients with non-blastoid as well as patients with blastoid MCL into groups with substantially different survival. Thus, standardized assessment of the Ki-67 index (Klapper et al. J Hematopathol 2009) should be routinely performed in clinical practice to allow a more comprehensive individual risk estimation of MCL patients. Further analyses will aim at the biological basis of this prognostic effect. Figure 1: Overall survival according to Ki-67 index (< vs. ≥ 30% from Determann et al., Blood 2008) in patients with non-blastoid (left) or blastoid (right) mantle-cell lymphoma (MCL) Figure 1:. Overall survival according to Ki-67 index (< vs. ≥ 30% from Determann et al., Blood 2008) in patients with non-blastoid (left) or blastoid (right) mantle-cell lymphoma (MCL) Figure 2 Figure 2. Disclosures Dreyling: Roche: Honoraria, Research Funding. Klapper:Roche: Research Funding.

Abstract 3201: Insulin-like growth factor 2 (IGF-2) mRNA binding protein 3 predicts poor prognosis and promotes cell proliferation in Ewing sarcoma

2016 ◽  
Author(s):  
Caterina Mancarella ◽  
Linda Calzolari ◽  
Stefano Ferrari ◽  
Davide Donati ◽  
Piero Picci ◽  
...  
Keyword(s):  
Cell Proliferation ◽  
Growth Factor ◽  
Ewing Sarcoma ◽  
Poor Prognosis ◽  
Binding Protein ◽  
Insulin Like Growth Factor ◽  
Mrna Binding Protein ◽  
Mrna Binding

scholarly journals Expression and effects of inhibition of type I insulin-like growth factor receptor tyrosine kinase in mantle cell lymphoma

Haematologica ◽  
2011 ◽  
Vol 96 (6) ◽  
pp. 871-880 ◽  
Author(s):  
D. Vishwamitra ◽  
P. Shi ◽  
D. Wilson ◽  
R. Manshouri ◽  
F. Vega ◽  
...  
Keyword(s):  
Growth Factor ◽  
Tyrosine Kinase ◽  
Mantle Cell Lymphoma ◽  
Receptor Tyrosine Kinase ◽  
Cell Lymphoma ◽  
Growth Factor Receptor ◽  
Type I ◽  
Insulin Like Growth Factor ◽  
Mantle Cell

Autocrine Regulation of Human Tumor Cell Proliferation by Insulin-Like Growth Factor II: anin-VitroModel*

Endocrinology ◽  
1990 ◽  
Vol 126 (6) ◽  
pp. 3033-3042 ◽  
Author(s):  
M. ANNE THOMPSON ◽  
ALISON J. COX ◽  
ROBERT H. WHITEHEAD ◽  
HELEN A. JONAS
Keyword(s):  
Cell Proliferation ◽  
Growth Factor ◽  
Tumor Cell ◽  
Human Tumor ◽  
Insulin Like Growth Factor ◽  
Tumor Cell Proliferation ◽  
Human Tumor Cell ◽  
Autocrine Regulation ◽  
Factor Ii

scholarly journals Insulin-like growth factor II mRNA-binding protein 3 promotes cell proliferation, migration and invasion in human glioblastoma

2019 ◽  
Vol Volume 12 ◽  
pp. 3661-3670 ◽  
Author(s):  
Chao Wu ◽  
Hongxin Ma ◽  
Guijun Qi ◽  
Fanyu Chen ◽  
Jiancheng Chu
Keyword(s):  
Cell Proliferation ◽  
Growth Factor ◽  
Binding Protein ◽  
Migration And Invasion ◽  
Insulin Like Growth Factor ◽  
Human Glioblastoma ◽  
Factor Ii ◽  
Mrna Binding Protein ◽  
Mrna Binding

Insulin-like growth factor 2 mRNA binding protein 2 promotes aerobic glycolysis and cell proliferation in pancreatic ductal adenocarcinoma via stabilizing GLUT1 mRNA

2019 ◽  
Vol 51 (7) ◽  
pp. 743-752 ◽  
Author(s):  
Shan Huang ◽  
Zheng Wu ◽  
Yunyun Cheng ◽  
Wenzhen Wei ◽  
Linlin Hao
Keyword(s):  
Cell Proliferation ◽  
Growth Factor ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Binding Protein ◽  
Aerobic Glycolysis ◽  
Ductal Adenocarcinoma ◽  
Insulin Like Growth Factor ◽  
Mrna Binding Protein ◽  
Mrna Binding ◽  
Glut1 Mrna

Abstract Insulin-like growth factor 2 mRNA binding protein 2 (IGF2BP2) is a member of the IGF2BP protein family consisting of IGF2BP1~3 with the capacity of binding to many transcripts and regulating RNA stability, localization, and translation. In this study, we discovered that expression of IGF2BP2 was upregulated and led to a poor prognosis in pancreatic ductal adenocarcinoma (PDAC). IGF2BP2 protein was gradually elevated from normal pancreas, pancreatic intraepithelial neoplasia to PDAC in an LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx1-Cre mouse model. Furthermore, we demonstrated that IGF2BP2 promoted aerobic glycolysis and PDAC cell proliferation through directly binding to and stabilizing GLUT1 mRNA. In summary, our study unveiled an important role of IGF2BP2 in PDAC development by modulating aerobic glycolysis and as a potential therapeutic target for PDAC treatment.

scholarly journals MicroRNA‑454‑3p inhibits cell proliferation and invasion in esophageal cancer by targeting insulin‑like growth factor 2 mRNA‑binding protein 1

2020 ◽  
Vol 20 (6) ◽  
pp. 1-1
Author(s):  
Aiting Yan ◽  
Cuizhu Wang ◽  
Liangfeng Zheng ◽  
Jiebo Zhou ◽  
Yan Zhang
Keyword(s):  
Cell Proliferation ◽  
Esophageal Cancer ◽  
Growth Factor ◽  
Binding Protein ◽  
Insulin Like Growth Factor ◽  
Mrna Binding Protein ◽  
Mrna Binding ◽  
Proliferation And Invasion

Epidermal growth factor receptor expression is associated with rapid tumor cell proliferation in renal cell carcinoma

1997 ◽  
Vol 28 (11) ◽  
pp. 1255-1259 ◽  
Author(s):  
Holger Mock ◽  
Guido Sauter ◽  
Niels Buchholz ◽  
Thomas C Gasser ◽  
Lukas Bubendorf ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Proliferation ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Tumor Cell ◽  
Growth Factor Receptor ◽  
Receptor Expression ◽  
Tumor Cell Proliferation ◽  
Epidermal Growth
Sign in / Sign up

Export Citation Format

Share Document